Immunohistochemical detection of the CXCR4 expression in tumor tissue using the fluorescent peptide antagonist Ac-TZ14011-FITC

Translational Oncology

Volumn 4, Issue 4, 2011, Pages 234-240

  van den Berg, Nynke S ^a   Buckle, Tessa ^a   Kuil, Joeri ^a   Wesseling, Jelle ^a   van Leeuwen, Fijs W B ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; FLUORESCEIN ISOTHIOCYANATE;

ARTICLE; BREAST CANCER; CANCER CELL; CELL MEMBRANE; CONTROLLED STUDY; ENDOCYTOSIS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; ISOTOPE LABELING; PROTEIN EXPRESSION; TUMOR CELL;

EID: 79960330460     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.11115     Document Type: Article

References (32)

1. Donzella GA, Schols D, Lin SW, Esté JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, De Clercq E, et al. (1998). AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 4(1), 72-77.
2. Tarasova NI, Stauber RH, and Michejda CJ (1998). Spontaneous and ligand-induced trafficking of CXC-chemokine receptor 4. J Biol Chem 273(26), 15883-15886.
3. Balkwill F (2004). Cancer and the chemokine network. Nat Rev Cancer 4(7), 540-550.
4. + T-cell sccumulation in rheumatoid arthritis synovium. J Immunol 165(11), 6590-6598.
5. Nanki T, Takada K, Komano U, Morio T, Kanegane H, Nakajima A, Lipsky PE, and Miyasaka N (2009). Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther 11(5), R149.
6. Andreas K, Lübke C, Häupl T, Dehne T, Morawietz L, Ringe J, Kaps C, and Sittinger M (2008). Key regulatory molecules of cartilage destruction in rheumatoid arthritis: an in vitro study. Arthritis Res Ther 10(1), R9.
7. Kang H, Watkins G, Douglas-Jones A, Mansel RE, and Jiang WG (2005). The elevated level of CXCR4 is correlated with nodal metastasis of human breast cancer. Breast 14, 360-367.
8. Balkwill F (2004). The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 14(3), 171-179.
9. Kulbe H, Levinson NR, Balkwill F, and Wilson JL (2004). The chemokine network in cancer-much more than directing cell movement. Int J Dev Biol 48(5-6), 489-496.
10. Arya M, Ahmed H, Silhi N, Williamson M, and Patel HRH (2007). Clinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand-receptor) interaction in cancer cell migration. Tumor Biol 28(3), 123-131.
11. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, et al. (2001). Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824), 50-56.
12. Woo SU, Bae JW, Kim CW, Lee JL, and Koo BW (2008). A significant correlation between nuclear CXCR4 expression and axillary lymph node metastasis in hormonal receptor negative breast cancer. Ann Surg Oncol 15(1), 281-285.
13. Andre F, Xia W, Conforti R, Wei Y, Boulet T, Tomasic G, Spielmann M, Zoubir M, Berrada N, Arriagada R, et al. (2009). CXCR4 expression in early breast cancer and risk of distant recurrence. Oncologist 14(12), 1182-1188.
14. Kato M, Kitayama J, Kazama S, and Nagawa H (2003). Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res 5(5), R144-R150.
15. Mirisola V, Zuccarino A, Bachmeier BE, Sormani MP, Falter J, Nerlich A, and Pfeffer U (2009). CXCL12/SDF1 expression by breast cancers is an independent prognostic marker of disease-free and overall survival. Eur J Cancer 45(14), 2579-2587.
16. Kang H, Watkins G, Parr C, Douglas-Jones A, Mansel RE, and Jiang WG (2005). Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer. Breast Cancer Res 7(4), R402-R410.
17. Huang X, Shen J, Cui M, Shen L, Luo X, Pei G, Jiang H, and Chen K (2003). Molecular dynamics simulations on SDF-1α: binding with CXCR4 receptor. Biophys J 84, 171-184.
18. Trent JO, Wang Z, Murray JL, Shao W, Tamamura H, Fujii N, and Peiper SC (2003). Lipid bilayer simulations of CXCR4 with inverse agonists and weak partial agonists. J Biol Chem 278(47), 47136-47144.
19. Zhang W, Navenot JM, Haribabu B, Tamamura H, Hiramatu K, Omagari A, Pei G, Manfredi JP, Fujii N, Broach JR, et al. (2002). A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. J Biol Chem 277(27), 24515-24521.
20. Tamamura H, Omagari A, Oishi S, Kanamoto T, Yamamoto N, Peiper SC, Nakashima H, Otaka A, and Fujii N (2000). Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes. Bioorg Med Chem Lett 10(23), 2633-2637.
21. Liang Z, Wu T, Lou H, Yu X, Taichman RS, Lau SK, Nie S, Umbreit J, and Shim H (2004). Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res 64(12), 4302-4308.
22. Huang EH, Singh B, Cristofanilli M, Gelovani J, Wei C, Vincent L, Cook KR, and Lucci A (2009). A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res 155(2), 231-236.
23. Hanaoka H, Mukai T, Tamamura H, Mori T, Ishino S, Ogawa K, Iida Y, Doi R, Fujii N, and Saji H (2006). Development of 111-In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors. Nucl Med Biol 33(4), 489-494.
24. Kuil J, Velders AH, and van Leeuwen FWB (2010). Multimodal tumor-targeting peptides functionalized with both a radio- and a fluorescent label. Bioconjug Chem 21(10), 1707-1719.
25. Li YM, Pan Y, Wei Y, Cheng X, Zhou BP, Tan M, Zhou X, Xia W, Hortobagyi GN, Yu D, et al. (2004). Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6(5), 459-469.
26. Nishizawa K, Nishiyama H, Oishi S, Tanahara N, Kotani H, Mikami Y, Toda Y, Evans BJ, Peiper SC, Saito R, et al. (2010). Fluorescent imaging of high-grade bladder cancer using a specific antagonist for chemokine receptor CXCR4. Int J Cancer 127, 1180-1187.
27. Oishi S, Masuda R, Evans B, Ueda S, Goto Y, Ohno H, Hirasawa A, Tsujimoto G, Wang Z, Peiper SC, et al. (2008). Synthesis and application of fluoresceinand biotin-labeled molecular probes for the chemokine receptor CXCR4. Chembiochem 9, 1154-1158.
28. Nomura W, Tanabe Y, Tsutsumi H, Tanaka T, Ohba K, Yamamoto N, and Tamamura H (2008). Fluorophore labeling enables imaging and evaluation of specific CXCR4-ligand interaction at the cell membrane for fluorescence-bases screening. Bioconjug Chem 19(9), 1917-1920.
29. Fischer T, Nagel F, Jacobs S, Stumm R, and Schultz S (2008). Reassessment of CXCR4 chemokine receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-2. PLoS One 3(12), e4069.
30. Kryczek I, Wei S, Keller E, Liu R, and Zou W (2007). Stromal-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. Am J Physiol Cell Physiol 292(3), C987-C995.
31. + hematopoietic progenitor cells. Stem Cells 22(6), 1015-1029.
32. Nimmagadda S, Pullambhatla M, and Pomper MG (2009). Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT. J Nucl Med 7(50), 1124-1130.